ArticleScientific reports2026
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pseudomonas aeruginosa is an important cause of infections in hospitalized paediatric patients, which can prolong hospital stays, increase medical care costs, and increase morbidity and mortality. The aim of this study was to describe the molecular characteristics of carbapenem-resistant P. aeruginosa (CR-PA) isolates obtained from paediatric patients, along with their clinical data, infection type, treatment, and outcome. From January 2018 to March 2020, 65 P. aeruginosa isolates were prospectively collected, and carbapenemases were detected. The genes mexR, nalC, nalD, and oprD were amplified, sequenced, and analysed. The sequence types (STs) were determined by Multilocus sequence typing. Clinical information on the origin, evolution, treatment, and outcome of the infections was collected. Most isolates (81.6%, n = 53) were carbapenemase-negative; 18.4% (n = 12) were carbapenemase producers, with IMP being the most common (7/12). In the sequences of the mexR, nalC and nalD genes, 25% (n = 16), 8.5%(n = 6), and 10.6%(n = 7), respectively, presented modifications in the open reading frame, and stop codons were observed in 17.3% of mexR and 2.1% of nalD sequences. Premature stop codons were present in 70.6% of the oprD sequences, and frameshift mutations were observed in 75.5%. The isolates were distributed among 35 ST; ST348 (16.9%, n = 11), ST309 (12.3%, n = 8), and ST389 (10.8%, n = 7) were the most frequent. High-risk clones (HRC) including ST358, ST309, ST389, ST395, ST234 and ST11 were detected. A total of 92% (n = 60) of patients with CR-PA had underlying health conditions, the most frequent being congenital disorders. The most common empirical therapy was a combination of meropenem and an aminoglycoside or colistin (52.6%, n = 34), while among definitive treatments, monotherapy was used in 67.7% of patients, and 29.2% received a two-drug combination. The complications were associated with mortality (RR = 2.5, p < 0.0001). A total of 89.2% of infections were hospital-acquired. Modification of the porin OprD was the main mechanism of carbapenem resistance among P. aeruginosa isolates; however, carbapenemase-producing strains were observed, mainly from the imipenemase (IMP) family. 60% of the isolates belonged to STs, considered HRC. Of the clinical variables analysed, only the presentation of complications was associated with mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.